Research programme: antifungals - Cumbre PharmaceuticalsAlternative Names: Antifungals research programme - Questcor/Cumbre Pharmaceuticals
Latest Information Update: 05 Dec 2003
At a glance
- Originator Questcor Pharmaceuticals
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 05 Dec 2003 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 05 Mar 2001 Preclinical development for Mycoses in USA (Unknown route)
- 05 Mar 2001 Tularik has licensed this antifungal research programme